[Construction and immunogenicity evaluation of chimerical DNA vaccine of human papillomavirus type 11].
OBJECTIVE
To construct chimerical DNA vaccine plasmid of human papillomavirus type 11 (HPV11) L1-E7, and to evaluate its immunogenicity.


METHODS
Molecular cloning techniques were used to construct recombinant plasmid pcDNA3 L1-E7 as a DNA vaccine. BALB/c mice were vaccinated with DNA recombinants through muscle injection.IL-2 and gamma-INF secreted by immunized spleens lymphocyte and HPV 11 L1 or E7 specific antibodies were assayed by ELISA method. Spleens lymphocyte proliferation was measured by MTT assay.


RESULTS
The chimerical DNA plasmid of pcDNA3 L1-E7 was constructed correctly. Specific anti-HPV11 E7 and L1 antibodies, specific lymphocyte proliferation and secretions of IL-2 and gamma-INF were detected in vaccinated mice.


CONCLUSIONS
Specific immune response, including cellular immunity and humoral immunity, could been detected in mice vaccinated with chimerical DNA vaccine of pcDNA3 L1-E7.
Huang
Zhao-Hui
ZH
No.4 People's Hospital Affiliated to Suzhou University, Wuxi 214062, China.
Li
Li-Hua
LH
Guo
Zhi-Jian
ZJ
Liu
Zhi-Hui
ZH
Ren
Jin-Dong
JD
Song
Ming-Xu
MX
Zhou
Xi-Ke
XK
Wang
Fei
F
Bi
Zhi-Gang
ZG
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D001483:Base Sequence; D005260:Female; D005818:Genetic Engineering; D052140:Human papillomavirus 11 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D030361:Papillomavirus Infections / Q000097:blood / Q000276:immunology* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D011897:Random Allocation; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA